Copyright © 2022 StrategyHelix Inc. All Rights Reserved.
Global DNA Vaccines Market 2022
DNA vaccines are third-generation vaccines. They contain DNA that codes for specific proteins (antigens) from a pathogen. DNA vaccines have emerged as a safer alternative to standard live and inactivated vaccines for treating human and animal viral diseases. They exhibit several advantages over traditional strategies in terms of safety, stability, ease of manufacturing, and immunogenicity. The global DNA vaccines market is poised to grow by US$ 14,948.0 million from 2022 to 2028, registering a CAGR of 30.1% during the forecast period, according to StrategyHelix.
The report provides up-to-date market size data for period 2018-2021 and forecast to 2028 covering key market aspects like sales value for DNA vaccines. The global DNA vaccines market is segmented on the basis of type, application, and end user. By type, the global DNA vaccines market has been segmented into clinical applications, research tools. The research tools segment was the largest contributor to the global DNA vaccines market in 2021. Based upon application, the global DNA vaccines market is categorized into genetic immunization, pDNA formulations. According to the research, the genetic immunization segment had the largest share in the global DNA vaccines market. On the basis of end user, the global DNA vaccines market has been segmented into animal health, biodefense, cancers, infectious diseases, others. The cancers segment held the largest revenue share in 2021.
The global DNA vaccines market is highly competitive. Some of the leading companies operating in the market are Astellas Pharma Inc., AstraZeneca plc, Bristol Myers Squibb Company (BMS), Gilead Sciences Inc., Johnson & Johnson, Merck KGaA, Novartis International AG, Pfizer Inc., Sanofi S.A.
The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the DNA vaccines market to help drive informed decision making for industry executives, policy makers, academic, and analysts.
Type: clinical applications, research tools
Application: genetic immunization, pDNA formulations
End user: animal health, biodefense, cancers, infectious diseases, others
Years considered: this report covers the period 2018 to 2028
Key Benefits for Stakeholders
– Get a comprehensive picture of the global DNA vaccines market
– Identify regional strategies and strategic priorities on the basis of local data
– Pinpoint growth sectors and trends for investment
Table of Contents
Part 1. Introduction
– Scope of the study
– Study period
– Geographical scope
– Research methodology
Part 2. DNA vaccines market overview
Part 3. Market breakdown by type
– Clinical applications
– Research tools
Part 4. Market breakdown by application
– Genetic immunization
– PDNA formulations
Part 5. Market breakdown by end user
– Animal health
– Infectious diseases
Part 6. Key companies
– Astellas Pharma Inc.
– AstraZeneca plc
– Bristol Myers Squibb Company (BMS)
– Gilead Sciences, Inc.
– Johnson & Johnson
– Merck KGaA
– Novartis International AG
– Pfizer Inc.
– Sanofi S.A.